dla pacjentów i lekarzy
Onkologia - aktualności medyczne dla lekarzy z roku 2020
EMA recommends Granting a marketing authorisation for Tucatinib
22.12.2020
On 10 December 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product tucatinib (Tukysa), intended for the treatment of HER2-positive locally advanced or metastatic breast cancer.
EMA recommends extension of indications for Avelumab
17.12.2020
On 10 December 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product avelumab (Bavencio). New indication concerns the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Care of the patient with metastatic pancreatic bancer: Looking to the future to make choices in the present
16.12.2020
Metastatic pancreatic cancer carries a poor prognosis. Chemotherapy dominates early treatment, and early treatment choices rely on both patient performance status and what treatment, if any, may be given in subsequent lines. Germline and somatic genomic testing can help expand treatment options.
EMA recommends granting a conditional marketing authorisation for Trastuzumab Deruxtecan
15.12.2020
On 10 December 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product trastuzumab deruxtecan (Enhertu), intended for the treatment of metastatic HER2-positive breast cancer.
EMA recommends extension of indications for Pembrolizumab
14.12.2020
On 10 December 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab (Keytruda). The CHMP adopted a new indication as follows.
Novel prognostic tool may help better predict disease recurrence and chemotherapy benefit in early breast cancer
11.12.2020
A new prognostic decision-making tool that uses both genetic information and clinical-pathologic features could help breast oncologists more accurately determine risk of disease recurrence and whether adjuvant chemotherapy is warranted for patients with certain breast cancers.
Second-line Sintilimab improves survival over Docetaxel in squamous non-small cell lung cancer
11.12.2020
Patients with previously treated advanced squamous NSCLC show less survival benefit with second-line chemotherapy than with PD-1 inhibitor. Sintilimab provided superior clinical benefit compared to docetaxel in patients with previously treated advanced and/or metastatic squamous non-small cell lung cancer (sqNSCLC), according to phase III study findings presented at the ESMO Immuno-Oncology Virtual Congress 2020.
Could PSMA PET/CT be considered a new standard in prostate cancer imaging?
10.12.2020
Conventional imaging with radionuclide bone scans and contrast-enhanced CT has long been the standard in prostate cancer imaging, for both detection and assessment of disease. Prostate-specific membrane antigen (PSMA) PET/CT has emerged as the most sensitive alternative imaging method for advanced prostate cancer.
Jak rozpoznać niedożywienie przed leczeniem?
08.12.2020
Niedożywienie białkowo-kaloryczne jest bardzo często związane z chorobą nowotworową. Bez względu na przyczynę, niedożywienie może być powodem zwiększenia występowania i natężenia powikłań pooperacyjnych, wstrzymania chemioterapii lub radioterapii, a co za tym idzie – zmniejszenia skuteczności leczenia choroby nowotworowej. Dlatego tak ważne jest wczesne rozpoznanie stanów niedożywienia u każdego chorego z nowotworem.
Patient-derived organoids: applying a living biomarker in rectal cancer
05.12.2020
Several studies have examined patient-derived organoids in primary and metastatic colorectal cancer, demonstrating correlations between organoid chemosensitivity and patient response to the same chemotherapy, with recent studies specifically evaluating patient-derived organoids in locally advanced rectal cancer undergoing neoadjuvant radiation therapy and chemotherapy.
Niedożywienie w raku jajnika – niekorzystny czynnik rokowniczy
04.12.2020
Spośród wszystkich nowotworów narządu rodnego rak jajnika charakteryzuje się najczęstszym występowaniem niedożywienia związanym z chorobą nowotworową, co z kolei jest czynnikiem ryzyka powikłań pooperacyjnych, włącznie z powikłaniami śmiertelnymi. Z tego powodu niezwykle ważna jest dbałość o odpowiednie przygotowanie żywieniowe pacjenta przed rozpoczęciem procesu leczenia.
Significantly longer PFS with first-line Pembrolizumab for MSI-H/dMMR mCRC
03.08.2020
Pembrolizumab led to significantly longer progression-free survival than chemotherapy in KEYNOTE-177 as first-line treatment for MSI-H/dMMR metastatic colorectal cancer. The authors wrote that programmed death 1 (PD-1) blockade has clinical benefit in MSI–high (MSI-H) or mismatch-repair–deficient (dMMR) tumours after previous therapy. It has emerged as effective therapy for MSI-H/dMMR metastatic CRC (mCRC) refractory to standard chemotherapy combinations.
Therapeutic targets could revolutionize the management of pancreatic cancer
03.12.2020
Despite recent advances in chemotherapy, pancreatic cancer remains notoriously treatment-resistant. PARP inhibitors have shown promise in treating patients with BRCA1/2-mutated pancreatic cancer, but further studies are needed to inform the sequencing of PARP inhibitor treatment, resistance mechanisms, and the role of maintenance treatment.
Problemy żywieniowe w chorobie nowotworowej – skąd czerpać wiedzę?
01.12.2020
W ostatnim czasie, w latach 2019 i 2020 pojawiły się na półkach księgarskich znakomite publikacje dotyczące leczenia żywieniowego, w tym leczenia żywieniowego chorych onkologicznych. W załączeniu przedstawiamy je wraz z krótkim opisem treści. Są one napisane przez lekarzy specjalizujących się w problemach leczenia żywieniowego, z wieloletnim doświadczeniem klinicznym, będącymi niekwestionowanymi autorytetami w tym temacie.
Problem niedożywienia u chorych z rakiem płuca poddanych chemioterapii
27.11.2020
W jednym z ostatnich badań oceniano stopień odżywienia w grupie 465 chorych z rakiem płuca. Oceny dokonywano w oparciu o standardowy kwestionariusz PG-SGA stosowany do analizy odżywienia pacjentów. Stan odżywienia analizowano przed chemioterapią oraz po 4 kursach leczenia.
Immunotherapy advances into the adjuvant and first-line metastatic settings for gastric and esophageal cancers
24.11.2020
The combination of immunotherapy and chemotherapy improves overall survival and progression-free survival compared with chemotherapy alone for patients with untreated metastatic gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma. Adjuvant nivolumab significantly improves median disease-free survival in patients with stage II/III esophageal/gastroesophageal junction cancer treated with trimodality therapy.
Olaparib maintenance reduces the risk of recurrence in newly diagnosed patients with advanced ovarian cancer harbouring a brca mutation
22.11.2020
Maintenance therapy with olaparib following platinum-based chemotherapy provided a substantial benefit with regard to progression-free survival (PFS) among women with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation (BRCAm), according to long-term SOLO1 findings presented at the ESMO Asia Virtual Congress 2020.
Antibody-based immunotherapy advances in prostate cancer
21.11.2020
Many prostate cancer clinical trials are investigating the combination of existing therapies, such as androgen deprivation therapy, chemotherapy, PARP inhibitors, and tyrosine kinase inhibitors, with immune checkpoint blockade. Several bispecific antibodies, antibody-drug conjugates, and targeted radionuclide therapies are showing early promising evidence of clinical activity in men with advanced prostate cancer.
Akademia raka piersi 2020
20.11.2020
Jak przebiega leczenie pierwotnie operacyjnego, luminalnego raka piersi? Czy przy napromieniowaniu okolic węzłowych należy zawsze napromieniać także pole z blizną? Czy intensyfikacja leczenia anty HER2 może przynieść korzyść? Na te i inne pytania udzielą odpowiedzi wybitni eksperci zgromadzeni podczas Akademii Raka Piersi 2020, której organizatorem jest PZWL Wydawnictwo Lekarskie i PTCHO.
ASCO releases guideline on systemic therapy for advanced HCC
19.11.2020
ASCO has released a new evidence-based clinical practice guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). Advanced HCC has transitioned from a disease where we had a single approved therapy for patients to one where we now have upwards of nine options.
Nowość w języku polskim - podręcznik „Pierwotne i wtórne nowotwory otrzewnej. Diagnostyka. Leczenie.”
18.11.2020
Podręcznik został napisany przez doświadczonych chirurgów i lekarzy innych specjalności, wykonujących zabiegi cytoredukcyjne nowotworów otrzewnej w jednym z najlepszych ośrodków na świecie – Peritoneal Malignancy Institute w Basingstoke w Wielkiej Brytanii. Ich wiedza i doświadczenie w leczeniu chorych z pierwotnymi i wtórnymi nowotworami otrzewnej zaowocowała wypracowaniem standardów postępowania i techniką operacyjną godnymi naśladowania.
The American Gastroenterological Association Guidance: When to Screen for Pancreatic Cancer
17.11.2020
The American Gastroenterological Association (AGA) has released a new Clinical Practice Update providing best practice advice for clinicians screening and diagnosing high-risk individuals with pancreatic cancer. In the “AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review” the authors provided the best practice advice statements to address key issues in the clinical management of these patients.
Leczenie przerzutów do otrzewnej w raku odbytnicy
16.11.2020
Przerzuty do otrzewnej w raku jelita grubego występują u około 10% chorych z nowo rozpoznanym nowotworem i u około 40% w przypadku wznowy miejscowej. Przerzuty raka odbytnicy do otrzewnej występują rzadziej niż w innych umiejscowieniach jelita grubego, ale stanową często problem terapeutyczny, zarówno ze względu na umiejscowienie jak i na bardziej agresywny charakter choroby.
Rak kolczystkomórkowy skóry 2020 - webinar
13.11.2020
Jak wygląda nowoczesna diagnostyka raka kolczystokomórkowego skóry? Jak przebiega optymalizacja ścieżki leczenia pacjenta z miejscowo zaawansowanym i uogólnionym rakiem kolczystokomórkowym skóry? Jak przebiega kwalifikacja do zabiegu operacyjnego przy dużym ryzyku oszpecenia chorego i/lub utraty funkcji narządu? Na te i inne pytania odpowiedzi udzielą wybitni eksperci prowadzący webinar.
Innowacyjne terapie w onkologii urologicznej 2020 - webinar
12.11.2020
Jakie są najnowsze terapie w onkologii urologicznej? Jak wygląda immunoterapia w leczeniu raka nerki i w przypadku raka pęcherza moczowego? Jaki przebieg ma leczenie cytotoksyczne w raku stercza? Na te i inne pytania odpowiedzi udzielą wybitni eksperci prowadzący webinar „Innowacyjne terapie w onkologii urologicznej”
FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
10.11.2020
Indications concern identification of BRCA1 and/or BRCA2 mutations in ovarian cancer eligible for treatment with rucaparib, PIK3CA mutations in breast cancer eligible for treatment with alpelisib, ALK rearrangements in non-small cell lung cancer eligible for treatment with alectinib, BRCA1, BRCA2, and/or ATM mutations in metastatic castration resistance prostate cancer (mCRPC) eligible for treatment with olaparib.
Akademia onkologii urologicznej 2020
09.11.2020
Jak zmienia się rola urologa w leczeniu raka stercza? Jak wygląda kwalifikacja do postępowania leczniczego u pacjentów ze świeżo rozpoznaną chorobą oraz nawrotem nowotworów zarodkowych jądra? Jak zmienia się standard postępowania w pierwotnie rozsianym raku nerki? Na te i inne pytania udzielą odpowiedzi wybitni eksperci zgromadzeni podczas Akademii Onkologii Urologicznej.
Pembrolizumab potential new standard of care for patients with metastatic esophageal cancer in second-line setting
06.11.2020
Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with PD-L1 CPS ≥ 10, with fewer treatment-related adverse events.
Benefit assessment of adding irinotecan to capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer
04.11.2020
Under the guidance of the UGT1A1 genotype, an increased irinotecan dose in combination with capecitabine-based chemoradiation significantly improved the clinical response rate with acceptable toxicities in Chinese patients with locally advanced rectal cancer. Ji Zhu from University Shanghai Cancer Center in Shanghai, China and colleagues investigated whether adding a second drug to neoadjuvant chemoradiation can improve the clinical outcome. They reported the results of the first phase III study to evaluate the use of the UGT1A1 genotype for guiding the irinotecan dose in this setting on 29 October 2020 in the Journal of Clinical Oncology.
Akademia Czerniaka 2020
29.10.2020
Jakie są perspektywy i aktualne wytyczne w leczeniu nowotworów skóry? Jaka jest rola chirurgii w diagnostyce i leczeniu czerniaków? Jaki jest udział dermatologa w diagnostyce i terapii nowotworów skóry? Na te i inne pytania odpowiedzi udzielą wybitni eksperci zgromadzeni podczas VII edycji Akademii Czerniaka, której organizatorem jest PZWL Wydawnictwo Lekarskie.
Adding advanced PET scans to radiation treatment plans for prostate cancer increases failure-free survival rates
28.10.2020
Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds. Among patients whose prostate cancer had returned after surgical removal of their prostate, 75.5% whose treatment integrated the PET molecular imaging were disease-free after three years, compared to 63% for whom only conventional imaging techniques were used to plan treatment. The increased survival rate persisted for up to four years.
Akademia nowotworów przewodu pokarmowego – nowości po ESMO i WCGIC
27.10.2020
Jakie są nowości w diagnostyce nowotworów przewodu pokarmowego, w leczeniu uzupełniającym i w radioterapii? Jak wygląda kwestia zachowania jakości życia u chorych poddawanych chemioterapii z powodu raka jelita? Jak powinno przebiegać leczenie celowane w 2 linii? Na te i inne pytania udzielą odpowiedzi wybitni eksperci zgromadzeni podczas II edycji Akademii Nowotworów Przewodu Pokarmowego.
Guideline update offers new directions about Trastuzumab emtansine for HER2-positive breast cancer
22.10.2020
About 10% to 20% of newly diagnosed breast cancers demonstrate overexpression of the HER2 protein. Several HER2-targeted therapies have been approved over the past several years for treatment in the adjuvant and metastatic setting (e.g., pertuzumab, lapatinib, and neratinib). However, for some women, disease recurrence does occur, and ongoing research continues to seek optimal therapeutics to give all women with HER2-positive disease the greatest chances at survival.
Post-ESMO: najważniejsze doniesienia z kongresu ESMO 2020 z zakresu leczenia raka płuca, piersi, jajnika i prostaty
21.10.2020
Tegoroczny Kongres Europejskiego Stowarzyszenia Onkologii Medycznej (ESMO) przyniósł wiele istotnych doniesień z zakresu leczenia raka płuca, piersi, jajnika i prostaty. Omówione one zostały podczas konferencji zorganizowanej przez Modern Healthcare Institute oraz Polską Koalicję Pacjentów Onkologicznych z udziałem ekspertów klinicznych.
Ponad miliard złotych mniej na terapie lekowe w planie finansowym NFZ
20.10.2020
INFARMA podziela głębokie zaniepokojenie ekspertów, klinicystów i parlamentarzystów sytuacją w systemie ochrony zdrowia w dobie COVID-19. Plan finansowy Narodowego Funduszu Zdrowia na 2021 rok zakłada bowiem zmniejszenie wydatków na refundację o kwotę ponad miliarda złotych w porównaniu do obecnego planu na 2020 rok. Taka sytuacja stwarza istotne zagrożenie zdrowia i życia pacjentów cierpiących na choroby przewlekłe (w tym nowotworowe).
Targeted therapy based on molecular profiling of malignant mesothelioma tumours is feasible
19.10.2020
First evidence that patients with malignant mesothelioma have gender specific differences in PDGFRα expression. Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings presented at the MAP 2020 Virtual Congress. In addition, molecular profiling also demonstrated gender specific differences in gene expression that could guide the choice of treatment.
Triple blockade demonstrates high response rates in metastatic melanoma
15.10.2020
Patients with unresectable and/or metastatic melanoma achieved high rates of durable response following treatment with a triplet regimen of PD-1 inhibitor, spartalizumab in combination with the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib. Findings from the efficacy, safety, and biomarker analysis of parts 1 and 2 of the randomised, placebo-controlled phase III COMBI-i trial (NCT02967692) were reported in the Nature Medicine on 5 October 2020.
HIPEC i zabiegi cytoredukcyjne - omówienie
14.10.2020
Przerzuty raka jelita grubego do otrzewnej mogą być skutecznie leczone jeśli możliwe jest wykonanie zabiegu cytoredukcyjnego, czyli chirurgicznego wycięcia wszystkich widocznych makroskopowo zmian przerzutowych. W celu radykalizacji zabiegu i uzyskania jak najlepszych wyników leczenia dodatkowo stosuje się zabieg dootrzewnowej chemioterapii perfuzyjnej w hipertermii - HIPEC.
Praktyczne wykorzystanie infuzorów w chemioterapii pacjentów z nowotworem przewodu pokarmowego – pytania i odpowiedzi
12.10.2020
Jak wygląda proces przygotowania oraz podania chemioterapii przy użyciu infuzorów? Na te pytanie odpowiedź uzyskają uczestnicy webinaru, którego organizatorem jest PZWL Wydawnictwo Lekarskie. Webinar odbędzie się 20 października, udział w nim jest bezpłatny.
Zrozumieć COVID-19 – najnowsza publikacja zespołu naukowców z Polskiej Akademii Nauk
09.10.2020
W obecnej chwili, wzrostu zachorowań na COVID-19, nie ma nic cenniejszego niż rzetelna wiedza z czym mamy do czynienia i jak się zachowywać. Publikacja znanych, szanowanych i bardzo racjonalnych naukowców, w tym lekarzy o specjalności chorób zakaźnych i anestezjologii i intensywnej terapii, ale także biologów, epidemiologów, wirusologów - czyni opracowanie wiarygodnym i pełnym w zakresie aktualnej wiedzy.
Raport „Innowacyjna onkologia”
07.10.2020
Wielopłaszczyznowe, kompleksowe, bazujące na innowacjach – jakie powinno być leczenie onkologiczne XXI wieku? Eksperci ze świata medycyny oraz ochrony zdrowia w raporcie „Innowacyjna onkologia”, który powstał z inicjatywy PZWL Wydawnictwa Lekarskiego i Polskiego Towarzystwa Onkologicznego przedstawiają analizę uwarunkowań, w jakich funkcjonuje polska onkologia oraz optymalne kierunki jej rozwoju, aby osiągnąć skuteczne leczenie nowotworów.
VI Warszawskie Seminarium UroRadioOnkologii
05.10.2020
W imieniu Komitetu Naukowego i Organizatora, serdecznie zapraszamy do udziału w VI Warszawskim Seminarium UroRadioOnkologii, które odbędzie się 12 listopada 2020 roku. Spotkanie odbędzie się w formule on-line. Prelegenci opowiedzą między innymi o onkouroekonomii, programach terapeutycznych, leczeniu pacjentów z rakiem prostaty czy o immunoterapii w raku pęcherza.
EMA recommends extension of indications for Niraparib
29.09.2020
New indication concerns maintenance treatment of adults with advanced ovarian cancer who are in response following completion of first-line platinum-based chemotherapy.
EMA recommends extension of indications for Atezolizumab
28.09.2020
New indication concerns a combination with bevacizumab for the treatment of adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy
Immunotherapy shows promise in mesothelioma
25.09.2020
Innovation in the frontline treatment of advanced malignant pleural mesothelioma (MPM) has been stagnant, with few treatment breakthroughs in the past 2 decades. Although immune checkpoint blockade (ICB) has become integrated into the first-line treatment strategy for multiple malignancies, it has yet to take a firm foothold in the therapeutic armamentarium of MPM.
EMA recommends extension of indications for Nivolumab and Ipilimumab
25.09.2020
New indication concerns their combination with 2 cycles of platinum-based chemotherapy in first-line treatment of metastatic NSCLC without sensitising EGFR mutation or ALK translocation
EMA recommends extension of indications for Olaparib
24.09.2020
New indications concern the maintenance treatment in combination with bevacizumab of ovarian cancer with HRD positive status and monotherapy of mCRPC with BRCA1/2 mutations
No survival advantage from radical hysterectomy in patients with cervical cancer and intraoperative detection of positive lymph node involvement
24.09.2020
No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of a positive pelvic lymph node (LN). These findings from a retrospective observational international ABRAX study were presented by Prof. David Cibula at the ESMO Virtual Congress 2020.
Abemaciclib improves iDFS in patients with HR+, HER2-, high-risk early breast cancer
23.09.2020
In what could be one of the biggest breakthroughs in early hormone receptor–positive (HR+) breast cancer therapy in nearly 20 years, abemaciclib when combined with endocrine therapy (ET) is the first CDK4/6 inhibitor to demonstrate a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) in patients with HR+, HER2-negative (HER2-), high-risk early-stage breast cancer, according to a new study presented during the ESMO Virtual Congress 2020 and published simultaneously in Journal of Clinical Oncology.
What role does checkpoint inhibition play in prostate cancer?
21.09.2020
Checkpoint inhibitors have revolutionized the treatment of many solid tumor types, such as melanoma, lung cancer, and renal cell carcinoma, but response rates to monotherapy in prostate cancer have been low, and studies show that the benefit of these treatments is limited to only a small group of patients.
The evolving role of Nivolumab, Ipilimumab, and other new therapies in patients with advanced hepatocellular carcinoma
18.09.2020
The treatment landscape for advanced hepatocellular carcinoma (HCC) has drastically changed in recent years, shifting toward targeted and immunotherapy options in both the first- and second-line settings. Because the majority of treatment options for HCC were approved only within the last 3 years, oncologists do not know how exactly to sequence them to achieve long-term benefit.
Overall survival significantly longer with Darolutamide in non-metastatic CRPC
15.09.2020
The results from the prespecified final analysis of overall survival (OS), all other secondary endpoints and long-term safety in the ARAMIS study indicate that metastasis-free survival (MFS) and OS were significantly longer with darolutamide than with placebo among men with non-metastatic, castration-resistant prostate cancer (CRPC) and a PSA doubling time of 10 months or less.
Webinar „Nowe terapie w leczeniu nowotworów skóry”
14.09.2020
Jakie są najnowsze osiągnięcia, postępy i zalecenia w zakresie leczenia nowotworów skóry? Jak leczyć chorego na zaawansowanego raka z komórek Merkla? Jak wygląda optymalna ścieżka leczenia pacjenta z miejscowo zaawansowanym i uogólnionym rakiem kolczystokomórkowym i podstawnokomórkowym skóry? Na te i inne pytania odpowiedzi udzielą wybitni eksperci prowadzący webinar „Nowe terapie w leczeniu nowotworów skóry”, którego organizatorem jest PZWL Wydawnictwo Lekarskie.
Five-year follow-up of adjuvant Dabrafenib plus Trametinib in resected stage III melanoma with BRAF mutations
11.09.2020
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study confirms that 12 months of adjuvant therapy with dabrafenib plus trametinib led to durable long-term benefit regarding relapse-free survival (RFS) in patients with resected stage III melanoma with BRAF V600 mutations.
Webinar „Diagnostyka i leczenie raka piersi”
10.09.2020
Jakie są najnowsze osiągnięcia, postępy i zalecenia w zakresie leczenia nowotworów skóry? Komu i kiedy jest i powinna być zlecana diagnostyka BRCA? Jakie jest miejsce inhibitorów PARP w leczeniu pacjentek z rakiem piersi (zgodnie z rejestracją EMA)? Na te i inne pytania odpowiedzi udzielą wybitni eksperci prowadzący webinar „Diagnostyka i leczenie raka piersi”, którego organizatorem jest PZWL Wydawnictwo Lekarskie. Webinar odbędzie się 23 września, udział w nim jest bezpłatny.
Radioterapia dla onkologów nieradioterapeutów
09.09.2020
Ukazała się pierwsza pozycja z serii wydawniczej „Akademia Radioterapii TARGET” przygotowana przez Wydawnictwo Memuar. Książka ma charakter kompendium dotyczącego radioterapii i skierowana jest przede wszystkim do lekarzy zajmujących się leczeniem nowotworów, nie będących radioterapeutami.
Akademia Leczenia Wspomagającego w Onkologii
08.09.2020
Jakie są najnowsze osiągnięcia, postępy i zalecenia w zakresie leczenia wspomagającego w onkologii? Jak zapobiegać przerzutom do kości i jak je leczyć? Jaki jest aktualny algorytm postępowania przy powikłaniach zakrzepowo-zatorowych? Na te i inne pytania odpowiedzi udzielą wybitni eksperci zgromadzeni podczas edycji Akademii Leczenia Wspomagającego w Onkologii, której organizatorem jest PZWL Wydawnictwo Lekarskie.
W gabinecie lekarza specjalisty. Onkologia
04.09.2020
Przedstawiamy kultową serię Wydawnictwa Lekarskiego PZWL „W gabinecie lekarza specjalisty. Onkologia”. To cykl publikacji przygotowanych przez specjalistów dla specjalistów, omawiający wybrane, najbardziej istotne zagadnienia, nowe trendy oraz innowacyjne terapie onkologiczne.
FDA approves first comprehensive pan-tumour liquid biopsy test for patients with advanced cancer
03.09.2020
US Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx, the comprehensive pan-tumour liquid biopsy test. It acts as a companion diagnostic to identify patients who may benefit from treatment with specific FDA-approved targeted therapies and a comprehensive genomic profiling test that reports genomic alteration results.
The role of immune checkpoint inhibitors in metastatic urothelial carcinoma: front-line maintenance approach emerges as the winner
02.09.2020
The treatment landscape for metastatic urothelial carcinoma has shifted in recent years with the introduction of novel therapeutic agents, such as immune checkpoint inhibitors (ICIs). Until recently, for eligible patients, upfront cisplatin-based chemotherapy remained the standard of care, with overall response and disease control rates of approximately 50% and 85% respectively.
Male patients with cancer at higher risk of severe disease course and mortality attributable to Covid-19
26.08.2020
The male sex appears to be a risk factor for severe disease and death due to COVID-19 in the cancer patient population according to findings from a systematic review and meta-analysis published on 24 August 2020 in the EClinicalMedicine, published by The Lancet. The finding may help in guiding the decision making in cancer care and patient counselling in the clinics especially because societies move towards re-opening and towards a new-normal.
Talazoparib does not prolong os in BRCA1/2-mutated, HER2-negative advanced breast cancer
21.08.2020
In BRCA1/2-mutated, HER2-negative advanced breast cancer, talazoparib did not significantly improve overall survival (OS) versus chemotherapy according to final OS analysis of the EMBRACA trial. The OS was generally consistent across subgroups including by prior platinum, hormone-receptor status, or line of treatment. Most patients received subsequent systemic treatments, which may have confounded the OS outcome.
New insights in tumor biology spark changes in colorectal cancer care
17.08.2020
Advances in tumor biology and tumor profiling increasingly enable the delivery of targeted therapies to patients with cancer. The identification of molecular biomarkers is causing a paradigm shift in colorectal cancer (CRC) care and beyond, because tumors are now treated based on their unique biologic/genetic features as opposed to anatomic location.
Postępowanie z pacjentami chorymi na raka podczas pandemii COVID-19
17.08.2020
W Annals of Oncology ukazały się najnowsze rekomendacje ekspertów ESMO dotyczące leczenia pacjentów onkologicznych w czasie pandemii Covid-19 zachęcające onkologów do nieprzerywania i nieodwlekania terapii przeciwnowotworowych, które mogą mieć wpływ na przeżycie. Podkreślono, że większość pacjentów z guzami litymi nie jest bardziej narażona na cięższy przebieg Covid-19 niż populacja ogółem.
Zalecenia postępowania diagnostyczno-terapeutycznego w raku nerkowokomórkowym
13.08.2020
W czasopiśmie „Onkologia w Praktyce Klinicznej” zostały opublikowane „Zalecenia postępowania diagnostyczno-terapeutycznego w raku nerkowokomórkowym”. Dokument ten został przygotowany przez wiodących ekspertów klinicznych: onkologów, urologów, radiologów i radioterapeutów. Są to innowacyjne i bardzo szczegółowe zalecenia Polskiego Towarzystwa Onkologii Klinicznej, które nakreślają trendy w nowoczesnym leczeniu raka nerki.
ASCO Updates Metastatic Pancreatic Cancer Guideline
10.08.2020
ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations. Last updated in 2018, this new version was triggered by novel evidence related to targeted therapies.
XXIII Kongres Polskiego Towarzystwa Onkologii Klinicznej
07.08.2020
W imieniu Polskiego Towarzystwa Onkologii Klinicznej zapraszamy do udziału w XXIII Kongresie PTOK, który odbędzie się w dniach 27–29 sierpnia 2020 roku w Krakowie. W trakcie Kongresu odbędą się sesje poświęcone wielu interesującym zagadnieniom, o których piszemy poniżej.
T-DM1 is active and well tolerated in patients with HER2-positive metastatic breast cancer and brain metastases
09.07.2020
The exploratory subgroup analysis of the KAMILLA trial represents the largest reported cohort of patients with HER2-positive metastatic breast cancer and brain metastases treated with T-DM1 in a prospective setting. The study team observed clinically meaningful antitumor activity in patients with and without prior radiotherapy, suggesting that T-DM1 is active, well tolerated in this difficult to treat population and warrants further exploration.
Education session to address recent advances in nuclear medicine theranostics for cancer
09.07.2020
Theranostics is a rapidly emerging field in nuclear medicine that relies on radiopharmaceuticals for both diagnostics and therapy. In the theranostic paradigm, diagnostic radiopharmaceuticals identify cancer tissues with a specific treatment target through imaging techniques, such as PET scans. In patients whose cancer has the treatment target, therapeutic radiopharmaceuticals then deliver cytotoxic levels of radiation to tumor tissues based on the presence of the target, while sparing the surrounding healthy tissues.
Novel strategies aim to tackle EGFR exon 20 insertions in lung cancer
09.07.2020
The effort to fight cancer with a targeted approach has been an integral part of oncology practice during the past few years. Currently, EGFR–tyrosine kinase inhibitors (TKIs), such as osimertinib, erlotinib, and gefitinib, comprise the standard of care as frontline options for non–small cell lung cancer (NSCLC) with sensitive mutations in the EGFR gene.
Melanoma at ASCO20: shortening, changing, and repurposing therapeutics in patients with unresectable disease
09.07.2020
Several studies presented during the ASCO20 Virtual Scientific Program explored unique treatment approaches for advanced and refractory disease, many of which are poised in the near term to become improvements to the standard of care in patients with unresectable melanoma.
FDA approves Pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer
08.07.2020
On 29 June 2020, the US Food and Drug Administration (FDA) approved pembrolizumab for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Approval was based on KEYNOTE‑177 (NCT02563002), a multicentre, international, open-label, active-controlled, randomised trial that enrolled 307 patients with previously untreated unresectable or metastatic MSI-H or dMMR colorectal cancer.
FDA approves Avelumab for urothelial carcinoma maintenance treatment
07.07.2020
On 30 June 2020, the US Food and Drug Administration (FDA) approved avelumab for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. Efficacy of avelumab for maintenance treatment of UC was investigated in the JAVELIN Bladder 100 trial (NCT02603432), a randomised, multicentre, open-label trial that enrolled 700 patients with unresectable, locally advanced or metastatic urothelial carcinoma that had not progressed with four to six cycles of first-line platinum-containing chemotherapy.
Expert perspective on ASCO20 gastrointestinal cancers research
03.07.2020
Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506). Donafenib was associated with a mild improvement in overall survival (OS) compared with sorafenib in the intention-to-treat population.
Expert perspective on ASCO20 immunotherapy research
03.07.2020
CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.
FDA approves combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive breast cancer
02.07.2020
On 29 June 2020, the US Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf for subcutaneous injection for the following indications. Use in combination with chemotherapy as - neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
Expert perspective on ASCO20 breast cancer research
02.07.2020
Patients with HER2-positive breast cancer have a 50% chance of developing brain metastases, resulting in poor overall survival (OS). Tucatinib is an oral HER2-specific tyrosine kinase inhibitor with activity in combination with capecitabine or trastuzumab in patients with HER2-positive breast cancer with or without brain metastases in original trials.
Outcomes from second-line chemotherapy in patients with cholangiocarcinoma and FGFR2 fusions
01.07.2020
Dr Milind Javle of the the University of Texas MD Anderson Cancer Center in Houston, TX, US and colleagues reported at ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July) that outcomes from second-line chemotherapy in patients with cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions are similar to those reported in the literature for all patients with cholangiocarcinoma regardless of genomic status and remain dismal.
Maintenance Olaparib in elderly patients with a germline BRCA mutation and metastatic pancreatic cancer
01.07.2020
Safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent irrespective of age. Furthermore, patients aged ≥65 years can derive long-term progression-free survival (PFS) benefit and durable tumour response from the maintenance treatment according to an additional analysis of the POLO trial.
EMA recommends granting a marketing authorisation for biosimilar Bevacizumab
30.06.2020
On 25 June 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Aybintio (bevacizumab), intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), renal cell cancer (RCC), epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
FDA approves Pembrolizumab for cutaneous squamous cell carcinoma
26.06.2020
On 24 June 2020, the US Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. Efficacy was investigated in KEYNOTE-629 (NCT03284424), a multicentre, multi-cohort, non-randomised, open-label trial.
Breast cancer research at ASCO20 Virtual Scientific Program highlights new avenues and better outcomes
25.06.2020
The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.
Top lung cancer research presented at the ASCO20 Virtual Scientific Program has implications for clinical practice
25.06.2020
Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Scientific Program and provided insights on how the new data will influence clinical practice.
New guideline for locally advanced esophageal cancer supports multimodality therapy and multidisciplinary treatment approach
24.06.2020
ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment. An Expert Panel developed the guideline based on 17 randomized controlled trials that met the inclusion criteria, and, where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma.
FDA grants accelerated approval to lurbinectedin for metastatic SCLC
20.06.2020
On 15 June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicentre open-label, multi-cohort study enrolling 105 patients with metastatic SCLC who had disease progression on or after platinum-based chemotherapy.
ASCO20 data show clear benefit for total neoadjuvant therapy in rectal cancer
19.06.2020
Although total neoadjuvant therapy has become the standard of care at many institutions for rectal cancer, there have not been prospective data showing a clear benefit until now, with results from OPRA, RAPIDO, and PRODIGE 23 presented during ASCO20 Virtual Scientific Program. The results from OPRA, PRODIGE 23, and RAPIDO not only shape the neoadjuvant approach in rectal cancer, but they may also move the approach of watch-and-wait into the mainstream.
Dla młodych naukowców – grant naukowy fundacji DKMS – druga edycja
17.06.2020
Ruszyła druga edycja „Grantu naukowego Fundacji DKMS”. Projekt został uruchomiony w zeszłym roku, w ramach inicjatywy „Program Rozwoju Polskiej Transplantologii i Wsparcia Pacjentów Cierpiących na Nowotwory Krwi”. Grant jest skierowany do młodych naukowców, którzy swoją pracę skupiają wokół transplantologii hematologicznej oraz terapii komórkowych. Został z entuzjazmem przyjęty w środowisku hematologicznym i uzyskał honorowy Patronat PTHiT.
FDA approves Brigatinib for ALK-positive metastatic NSCLC
28.05.2020
On 22 May 2020, the US Food and Drug Administration approved brigatinib for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Esmo Breast Cancer Virtual Meeting 2020: Results in hormone receptor-positive and tnbc subgroups from the phase III BROCADE3 trial
27.05.2020
In the BROCADE3 study conducted in patients with gBRCA-associated advanced breast cancer, the addition of veliparib to carboplatin plus paclitaxel with continuation of veliparib monotherapy at intensified dose and schedule if chemotherapy was withdrawn prior to disease progression led to improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive disease and in patients with triple negative breast cancer (TNBC).
Incorporating immunotherapy into the management of unresectable recurrent or metastatic head and neck cancer
27.05.2020
Despite the approvals of immunotherapeutic agents in recurrent or metastatic disease (R/M) head and neck squamous cell carcinoma (HNSCC), questions still remain regarding the optimal use of checkpoint inhibitors.
FDA approves Atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression
27.05.2020
On 18 May 2020, the US Food and Drug Administration approved atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), with no EGFR or ALK genomic tumour aberrations.
FDA approves Nivolumab plus Ipilimumab for first-line metastatic NSCLC with PD-L1 tumour expression ≥1%
26.05.2020
On 15 May 2020, the US Food and Drug Administration approved the combination of nivolumab plus ipilimumab as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 ≥1%, as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
ESMO Breast Cancer Virtual Meeting 2020: Results of an interim analysis of the PHranceSCa study
25.05.2020
Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.
ESMO Breast Cancer Virtual Meeting 2020: Final results of the LOTUS study
25.05.2020
Final analysis of the LOTUS trial, after deaths in 70% of study population, shows numerically longer overall survival (OS) with ipatasertib plus paclitaxel versus placebo plus paclitaxel in patients with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC).
New cancer cachexia guideline addresses common quality-of-life issue
25.05.2020
ASCO recently released a new evidence-based guideline regarding the clinical management of cancer cachexia in adult patients with advanced cancer.1 The guideline is the result of a literature review that included 20 systematic reviews and 13 randomized clinical trials.
FDA approves Olaparib for HRR gene-mutated metastatic castration resistant prostate cancer
25.05.2020
On 19 May 2020, the US Food and Drug Administration approved olaparib for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.
Bezpłatny cykl: Virtual Medical Masterclass – Rak piersi
22.05.2020
Od maja ruszyły zapisy do udziału w bezpłatnym cyklu Virtual Medical Masterclass – Rak Piersi. Cykl wydarzeń online skierowany jest przede wszystkich do onkologów, chirurgów onkologicznych, radioterapeutów oraz lekarzy innych specjalizacji zaangażowanych w leczenie chorych na raka piersi.
FDA approves Ripretinib for advanced gastrointestinal stromal tumour
21.05.2020
On 15 May 2020, FDA approved ripretinib, for adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
The role of lymphadenectomy in muscle-invasive bladder cancer
21.05.2020
A multitude of studies have tested the effect of a more extensive pelvic lymph node dissection (PLND) during radical cystectomy (RC) aiming to achieve a prolonged recurrence-free and overall survival from the surgical treatment.
Patients with mCRPC have better HRQoL when treated with Olaparib
21.05.2020
Men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving enzalutamide or abiraterone and who had homologous recombination repair (HRR) gene alterations demonstrated longer progression-free survival and better measures of response when treated with olaparib than enzalutamide or abiraterone.
Atezolizumab combined with Bevacizumab in unresectable HCC
20.05.2020
In patients with unresectable hepatocellular carcinoma (HCC) included in the IMbrave150 study, the combination of atezolizumab and bevacizumab was associated with better progression-free survival (PFS) and overall survival (OS) outcomes, response rate and preservation of quality of life (QoL) than a treatment with sorafenib.
FDA grants accelerated approval to Rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
20.05.2020
On 15 May 2020, FDA granted accelerated approval to rucaparib for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Wspólne wytyczne TChP i PTChO dla udzielania akredytacji Towarzystw dla ośrodków wykonujących zabiegi cytoredukcyjne oraz procedury HIPEC
19.05.2020
W następstwie dyskusji związanej z potrzebą oceny jakości i wyników leczenia, na wniosek Sekcji Nowotworów Otrzewnej Polskiego Towarzystwa Chirurgii Onkologicznej opracowano warunki akredytacji i powołano Komisję Akredytacyjną dla ośrodków wykonujących zabiegi cytoredukcyjne i HIPEC w leczeniu pierwotnych i wtórnych nowotworów otrzewnej. Źródło: Towarzystwo Chirurgów Polskich
Webinar: Metody leczenia wczesnego raka piersi – dziś i jutro
15.05.2020
Webinar ma celu uporządkowanie wiedzy i przedstawienie algorytmów terapeutycznych w kontekście perspektyw leczenia wczesnego raka piersi. Podczas webinarium dr n. med. Agnieszka Jagiełło-Gruszfeld omówi tematy dotyczące obecnych metod leczenia wczesnego raka piersi jak i perspektyw, w tym najnowszych badań i produktów leczniczych będących w trakcie procesu refundacyjnego. Nie zabraknie również doniesień z ostatnich zagranicznych konferencji naukowych.
NK cells emerge as potentially useful targets for extending survival in triple-negative breast cancer
14.05.2020
Triple-negative breast cancer (TNBC) is a highly aggressive disease that is resistant to endocrine therapy and anti-HER2 molecular targeted treatments. However, results from a new study suggest that natural killer (NK) cells may be an effective alternative focus for future immune-based treatments to improve survival in patients with TNBC.
Vitamin D reduces incidence of advanced cancers in normal-weight individuals
13.05.2020
Vitamin D supplementation reduced the incidence of advanced cancer in a large study of older adults (men ≥ 50 years old, women ≥ 55 years old), with adults of normal body mass index (BMI) deriving the most benefit.
FDA approves Olaparib plus Bevacizumab as maintenance treatment for ovarian cancer
13.05.2020
On 8 May 2020, the US Food and Drug Administration (FDA) expanded the indication of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
Study reveals association between immune cell profiles and functional decline in women with breast cancer receiving chemotherapy
13.05.2020
Higher prechemotherapy lymphocytes and lower neutrophil:lymphocyte ratio (NLR) were found to correlate with an increased risk of functional decline and reduced ability to regain baseline physical function in women with breast cancer in a recent study from the University of Rochester.
FDA approves Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
12.05.2020
On 8 May 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Selpercatinib for the following indications: adult patients with metastatic RET fusion-positive non-small cell lung cancer, adult and paediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
EMA Does Not Recommend Extending the Use of Pembrolizumab
11.05.2020
On 30 April 2020, the European Medicines Agency (EMA) announced that it has finalised its assessment of an application for the use of pembrolizumab (Keytruda) alone as a first-line treatment in patients with non-small cell lung cancer (NSCLC) and low levels of the protein PD-L1.
EMA recommends extension of indications for Encorafenib
07.05.2020
On 30 April 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Encorafenib.
The current treatment paradigm of early-stage HPV-related oropharynx cancer
07.05.2020
Head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer morbidity and mortality worldwide. It is the sixth most common cancer globally and attributed to 300,000 deaths each year.1 However, over the past decade evidence has proved that HNSCC is not a monolithic disease, and tumors driven by HPV represent a clear and distinct subset of HNSCC.
FDA approves Niraparib for first-line maintenance treatment of advanced ovarian cancer
06.05.2020
On 29 April 2020, the US Food and Drug Administration (FDA) approved Niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
FDA approves new dosing regimen for pembrolizumab
04.05.2020
On 28 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.
Using immune checkpoint inhibition for head and neck cancer in the curative setting
04.05.2020
Restoring the anti-tumoral immune response is an important cancer treatment strategy. The most effective means to do this to date has been interruption of immune tolerance signaling through the PD-1/PD-L1 pathway. Such immune checkpoint inhibition through the PD-1 targeting antibodies, pembrolizumab and nivolumab, has reproducible activity in head and neck cancer, and impacts survival in the first-line metastatic and cisplatin-refractory settings.
Kinase fusions in ESR1 wild-type metastatic breast cancer
30.04.2020
Results of the study published on 26 April 2020 in the Annals of Oncology show that kinase fusions are enriched in ESR1 wild-type metastatic breast cancer after progression on endocrine therapy. The authors emphasised that fusion testing of metastatic breast cancers upon progression to endocrine therapy may provide new therapeutic options in this setting.
Mortality among thoracic cancer patients with COVID-19 is unexpectedly high
28.04.2020
The data, presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting by Dr Marina Chiara Garassino from Fondazione IRCCS Istituto Nazionale Tumori in Milan, Italy, includes the results for the first 200 patients enrolled in the registry up to 12 April 2020, and represents the first large dataset for patients with thoracic cancers infected with COVID-19.
First report on the prognosis of COVID-19 patients with cancer in the US
24.04.2020
A group of clinicians from the Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, US sought to determine if cancer patients with COVID-19 in the US have a poorer prognosis. In an article published in the Annals of Oncology, they analysed the electronic medical records of Mount Sinai Health System in New York City and found 334 patients (6%) with cancer among 5,688 patients diagnosed with COVID-19.
Long-term outcomes and responses to retreatment in patients with Melanoma treated with PD-1 blockade
23.04.2020
We retrospectively analyzed all patients with nonuveal, unresectable stage III/IV melanoma treated with single-agent anti–PD-1 therapy at Memorial Sloan Kettering from 2009-2018 who had discontinued treatment and had at least 3 months of follow-up after discontinuation (396 patients).
FDA approves Tucatinib for patients with HER2-positive metastatic breast cancer
22.04.2020
On 17 April 2020, the US Food and Drug Administration (FDA) approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
FDA grants accelerated approval to Pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
22.04.2020
On 17 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
FDA approves Mitomycin for low grade upper tract urothelial cancer
20.04.2020
On 15 April 2020, the US Food and Drug Administration (FDA) approved Mitomycin for adult patients with low grade upper tract urothelial cancer. Efficacy determination was based on OLYMPUS (NCT02793128), an ongoing, single-arm, multicentre trial enrolling 71 patients.
Webinar: Rak jelita grubego – aktualne dylematy i problemy w leczeniu
18.04.2020
PZWL Wydawnictwo Lekarskie zaprasza 28 kwietnia (wtorek) o godzinie 18:00 do udziału w bezpłatnym webinarium. Podczas spotkania prof. Lucjan Wyrwicz omówi aktualne dylematy i problemy w leczeniu pacjentów chorych na raka jelita grubego i odpowie na Państwa pytania w tym zakresie.
Cancer Core Europe Urges To Close Key Knowledge Gaps on COVID-19 in Cancer Patients
17.04.2020
Scientific evidence is lacking in many domains as COVID-19 is a novel disease. Such situation prompted decision making processes in healthcare based on expert opinion. An article published on 16 April 2020 in the Nature Medicine features how seven comprehensive cancer centres within Cancer Core Europe have reorganised in a short time as a response to COVID-19 pandemic.
Utilizing Neoadjuvant Immunotherapy Combination in Triple-Negative Breast Cancer
10.04.2020
Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer and is often aggressive with worse outcomes compared with other breast cancer subtypes. TNBC exhibits the strongest immunogenicity among all breast cancer subtypes1 and serves as the ideal testing ground for immune modulation in an attempt to improve survival outcomes.
Protecting Medical Staff to Ensure Cancer Patients Can Safely Receive Care During the Pandemic
07.04.2020
As the proportion of healthcare workers with COVID-19 has rapidly increased in many countries since the beginning of the outbreak, implementing efficient measures to protect medical teams has become a top priority globally, with clear benefits for the quality of care in oncology too. With Antonio Passaro, European Institute of Oncology (IEO), Milan, Italy
Managing of Prostate Cancer During the COVID-19 Pandemic
06.04.2020
During the COVID-19 global pandemic,cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the high morbidity and mortality of COVID-19, especially in patients of older age, patients with comorbidities, and those with cancer.
Rekomendacje diagnostyczno-terapeutyczne u chorych na czerniaki
03.04.2020
Via Medica zaprasza do udziału w Virtual Meeting: Rekomendacje diagnostyczno-terapeutyczne u chorych na czerniaki w sytuacji ograniczonych zasobów i restrykcji związanych z pandemią SARS-CoV-2. Webinar odbędzie się we wtorek 7 kwietnia, w godzinach 18.00-20.00. Więcej informacji na stronie melanoma.viamedica.pl
ASCO Coronavirus Resources
02.04.2020
As the coronavirus (COVID-19) continues to spread, American Society of Clinical Oncology is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that individuals with cancer receive high-quality care. ASCO has compiled a wide range of resources to support clinicians, the cancer care delivery team, and patients with cancer. This is a rapidly evolving situation and ASCO resources will be updated on a regular basis.
COVID-19 - Impact in oncology
02.04.2020
Polskie Towarzystwo Chirurgii Onkologicznej poleca uwadze polskich onkologów, w tym chirurgów onkologicznych, przygotowane przez European School of Oncology kompendium wiedzy w formie rekomendacji oraz e-wykładów dotyczących postępowania z chorymi na nowotwory w dobie pandemii COVID-19.
Podręcznik prewencji i leczenia COVID-19
01.04.2020
Dzięki inicjatywie studentów z Uniwersytetu Medycznego w Poznaniu została przetłumaczona na język polski publikacja „Handbook of COVID-19 Prevention and Treatment”, opracowana przez naukowców z Chin. Pod podanym poniżej linkiem można pobrać najbardziej aktualną wersję tłumaczenia.
Zostań w domu z nauką i PWN. Wsparcie pracy zdalnej środowiska naukowego
01.04.2020
Pandemia COVID-19 diametralnie zmieniła naszą rzeczywistość. Przyszło nam się mierzyć z wyzwaniami, na które nikt nie był przygotowany. Rewolucja nie ominęła świata nauki. Z dnia na dzień funkcjonowanie uniwersytetów i instytucji badawczych przeniosło się do przestrzeni wirtualnej. Środowisko akademickie, naukowe straciło swobodę dostępu do zasobów bibliotecznych, laboratoriów, sal wykładowych.
Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic: Executive Summary
31.03.2020
The COVID-19 pandemic poses unprecedented challenges for patients, clinicians and health care systems. We assembled representatives from multiple cancer care organizations with expertise in the multidisciplinary management of breast disease to provide preliminary recommendations for the triage and treatment of patients with breast disease amidst the COVID-19 pandemic. These are recommendations, and are not intended to supersede individual physician judgement, nor institutional policy or guidelines.
Findings from a Retrospective Case Study of COVID-19 Infection in Cancer Patients in Wuhan: An Emphasis on Severe Events
30.03.2020
A study team composed from clinicians from three hospitals in Wuhan, China, led by Dr Min Zhou of the Department of the Respiratory and Critical Care Medicine, Tongji Hospital, performed a retrospective case study of clinical features among 28 patients with cancer and COVID-19 infection. In particular, they analyzed the risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or death. Their series was associated with poor outcomes. There was increased risk of developing severe events, especially if the last antitumour treatment was within 14 days of COVID-19 diagnosis.
Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 — stanowisko Polskiego Towarzystwa Onkologii Klinicznej
26.03.2020
Do powszechnej wiedzy należy już fakt, że populacją najbardziej narażoną na powikłania i śmierć w wyniku zarażenia SARS-CoV-2 są osoby w podeszłym wieku z chorobami współistniejącymi. Ponieważ większość (> 60%) przypadków nowotworów rozpoznaje się po 65. roku życia, a w Polsce obecnie żyje około miliona osób z rozpoznaniem choroby nowotworowej (w tym duża grupa jest w trakcie aktywnego leczenia), nie ulega wątpliwości, że jest to populacja szczególnego ryzyka.
The Blind Leading the Blind: COVID-19, Cancer, and the Need for More Data
26.03.2020
People with compromised immune systems and/or major medical problems, including patients with active cancer and cancer survivors, are at an increased risk for hospitalization and death from COVID-19. More than 30 cancer centers and other organizations have joined to collaborate on the CCC19 Registry, a survey tool allowing health care professionals to report patients whom they are treating for cancer and also have or are presumed to have COVID-19.
Investigators Explore Past Coronavirus Experiences to Help Inform Care During COVID-19 Pandemic
26.03.2020
Study investigated the features of oncology patients with confirmed Middle East respiratory syndrome (MERS) at the Ministry of National Guard Health Affairs-Riyadh during the outbreak of June 2015 to determine the clinical course and outcome of affected patients.
Treating HR-/HER2-Positive Metastatic Breast Cancer in 2020
25.03.2020
The treatment of HR-positive/HER2-positive MBC is an evolving field. Our multicenter, retrospective cohort analysis of more than 6,000 records of patients with HR-positive/HER2-positive stage IV breast cancer suggests that hormonal therapy is the more common care path used in first-line treatment. Furthermore, when combined with anti-HER2 therapy, this regimen may provide the best survival outcomes.
Exploring the Role of Adjuvant Postoperative Radiotherapy in Breast Cancer Treatment
24.03.2020
Adjuvant radiotherapy is typically delivered to patients with breast cancer with the goal of decreasing local-regional recurrence, which translates to a long-term survival benefit in appropriately selected patients. For node-negative breast cancer with higher T stages and breast cancer with one to three nodal metastases, the addition of regional nodal radiation has been more recently associated with not only a local-regional control benefit but also an equal (if not greater) disease-free survival benefit.
The Treatment of Patients With Cancer and Containment of COVID-19: Experiences From Italy
20.03.2020
Very limited data are available for patients with cancer during COVID-19 epidemics. In a retrospective analysis including 1,572 COVID-19 cases, authors identified 18 patients with cancer. Patients with cancer were observed to have a higher risk of severe events (a composite endpoint defined as the percentage of patients being admitted to the ICU requiring invasive ventilation, or death) compared with patients without cancer. Moreover, patients who underwent chemotherapy or surgery in the past month had a numerically higher risk of clinically severe events than did those not receiving chemotherapy or surgery.
How to Manage Cancer Care during COVID-19 Pandemic
19.03.2020
Experts from the Seattle Cancer Care Alliance (SCCA) - a Member Institution of the National Comprehensive Cancer Network - are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic.
COVID-19 infekcja wywołana koronawirusem SARS-CoV-2
16.03.2020
W związku z epidemią zakażeń koronawirusem SARS-CoV-2 i szczególnym zagrożeniem dla osób ze współistniejącymi chorobami przewlekłymi, z obniżoną odpornością oraz osób starszych zamieszczamy materiał informacyjny dotyczący COVID-19.
ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer
12.03.2020
ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer. The guideline Expert Panel took into account previously published guidelines from around the world including guidelines from the National Comprehensive Cancer Network, European Society for Medical Oncology, The United Kingdom’s National Institute for Health and Care Excellence and more.
Use of Both, MRI-Targeted and 12-Core Systematic Biopsies in Prostate Cancer
12.03.2020
In a study that involved 2013 men with elevated prostate specific antigen, the use of both, magnetic resonance imaging (MRI)-targeted and 12-core systematic biopsies was more effective at detecting clinically significant prostate cancers than either biopsy method alone. The results are published on 5 March 2020 in The New England Journal of Medicine.
What’s Next in Immunotherapy for Pancreatic Cancer? New Immune Cell Type May Be Key
11.03.2020
Current immunotherapies don’t work for most people with cancer. Researchers have identified an overlooked immune cell type that may react to targeted therapies to rally a more powerful immune response in more cancer patients.
Konferencja „Standardy i nowości w onkologii spersonalizowanej i interdyscyplinarnej”
09.03.2020
Tym razem szczególny nacisk zostanie położony na standardy i nowości w onkologii interdyscyplinarnej i spersonalizowanej. Chcemy Państwu zaprezentować nowoczesną, a więc interdyscyplinarną onkologię, czyli łączącą w walce o wspólny cel przedstawicieli różnych specjalizacji.
EORTC Updates QoL Module in Breast Cancer
06.03.2020
A group of researchers published in the February 2020 issue of the Annals of Oncology about process of updating and testing of the European Organization for Research and Treatment of Cancer (EORTC) questionnaire to assess quality of life (QoL) in breast cancer patients. The final updated module contains a total of 45 items from which 22 are new.
Platinum-based Agents are Not Superior to Standard Chemotherapy for Patients with Breast Cancer Who Carry BRCA Mutations
06.03.2020
Led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC), a first-of-its-kind study provided new evidence about the optimal way to treat patients who carry BRCA mutations – also known as BRCA carriers – who have been diagnosed with breast cancer. The new data come from the INFORM trial, the results of which appeared in the Journal of Clinical Oncology.
5. Edycja Akademii Raka Piersi
04.03.2020
Polskie Towarzystwo Chirurgii Onkologicznej i PZWL zapraszają do udziału w kolejnej edycji Akademii Raka Piersi. Podczas konferencji zostaną przedstawione aktualne zasady leczenia w formie algorytmów sporządzonych osobno dla chorych z rakami luminalnymi, HER2-dodatnimi i trójujemnymi. Będą one omawiane przez wielodyscyplinarny zespół specjalistów – złożony z chirurga, onkologa klinicznego i radioterapeuty – zgodnie z chronologią leczenia.
EMA Started a Review of Trabectedin
04.03.2020
European Medicines Agency (EMA) announced on 28 February 2020 that its Committee for Medicinal Products for Human Use (CHMP) has started a review of trabectedin (Yondelis), the cancer medicine used to treat ovarian cancer and soft-tissue sarcoma. The review started after a clinical study OVC-3006, which investigated the use of Yondelis in patients with ovarian cancer, was stopped ahead of time.
EMA Recommends Extension of Therapeutic Indications for Brigatinib
03.03.2020
On 27 February 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product brigatinib (Alunbrig). Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
FDA Approves Neratinib in Combination with Capecitabine for Metastatic HER2-positive Breast Cancer
02.03.2020
On 25 February 2020, the US Food and Drug Administration (FDA) approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for management of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
Current and Future Applications of Circulating-Tumor DNA in Lung Cancer
02.03.2020
The recent advent of cell-free DNA (cfDNA) or circulating-tumor DNA (ctDNA) platforms to genotype lung cancer has drastically altered the diagnostic paradigm in NSCLC. These platforms have a number of advantages: They are minimally invasive, have a rapid turnaround time, and can be performed serially. In addition, molecular alterations identified in ctDNA seem to be as predictive of response to targeted therapies as those identified in tissue.
Akademia Onkologii Urologicznej 2020
28.02.2020
Zapraszamy do udziału w Akademii Onkologii Urologicznej, której celem jest przybliżenie postępów i omówienie standardów postępowania z pacjentem chorym na nowotwory wywodzące się z układu moczowego i płciowego mężczyzny – z perspektywy urologa, onkologa i radioterapeuty.
Abbreviated MRI outperforms 3D mammograms at finding cancer in dense breasts
27.02.2020
According to a study published today in the Journal of the American Medical Association (JAMA), abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue.
Largest Real World Dataset of Immune Checkpoint Inhibitors in Melanoma Treatment Demonstrates Similar Outcomes to Randomised Clinical Trials
26.02.2020
Findings from a largest real world dataset in metastatic melanoma setting demonstrate rapid uptake of immune checkpoint inhibitors and patient outcomes similar to those achieved in randomised clinical trials. Use of emergency services varied by regimen, with colitis dominating hospitalisation after treatment with ipilimumab or ipilimumab plus nivolumab treatment. The results were presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.
Real-World Data Validation of Association Between Immunoregulatory Molecules Expression and Targetable Cancer Genes
25.02.2020
There may be a role for combining targets identified by next-generation sequencing along with patterns of immunoregulatory molecules expression to better guide future design of clinical trials in various cancer types in a tissue-agnostic fashion according to an independent, validated real-world dataset of immunoregulatory molecules in the presence of certain gene mutations. The findings were presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.
Predicting immunotherapy success
25.02.2020
One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.
WHO Estimation of Cervical Cancer Mortality
24.02.2020
Findings from a comparative modelling analysis in 78 low-income and lower-middle-income countries (LMICs) performed by the World Health Organization (WHO) Cervical Cancer Elimination Modelling Consortium emphasise the importance of acting immediately on three fronts to scale up human papillomavirus (HPV) vaccination, screening, and treatment for pre-invasive and invasive cervical cancer.
Study shows long-term survival benefit for certain patients with advanced lung cancer
24.02.2020
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda). The drug is one of the first checkpoint inhibitors to be developed and used in cancer treatment. The findings are published online today in the Journal of Clinical Oncology.
First-Line Treatment of Patients With Advanced NSCLC and High PD-L1 Expression: Immunotherapy With or Without Chemotherapy?
21.02.2020
Currently, whether to treat patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression with first-line immunotherapy with or without chemotherapy (platinum doublet) is based on clinician discretion, as both are considered standards of care. There are no currently published randomized clinical trials comparing these treatment options.
Talazoparib Shows Encouraging Antitumour Activity in Docetaxel Pretreated mCRPC
21.02.2020
On behalf of TALAPRO-1 investigators, Prof. Johann de Bono presented at 2020 Genitourinary Cancers Symposium the results of first interim analysis of the phase II trial with PARP inhibitor talazoparib performed among patients with DNA damage repair (DDR) mutations and docetaxel pretreated metastatic castration-resistant prostate cancer (mCRPC). The study team found that monotherapy with talazoparib demonstrated encouraging antitumour activity in this population, especially in patients with BRCA1/2 mutations. The treatment was well tolerated.
Neoadjuvant Chemo-Immunotherapy Yields Good Pathologic Response Rates in Muscle-Invasive Bladder Cancer
20.02.2020
The combination of nivolumab with gemcitabine and cisplatin in the neoadjuvant setting was well tolerated and resulted in promising pathologic response rates in patients with muscle-invasive bladder cancer (MIBC), according to results of the phase II BLASST-1 study.
HIF-2ɑ Inhibitor, Novel TKI Show Some Progress in Early Advanced RCC
20.02.2020
Two novel agents have shown promise in early-phase trials of patients with advanced clear cell renal cell carcinoma (ccRCC). One agent, sitravatinib, is a multitargeted tyrosine-kinase inhibitor (TKI) administered in combination with nivolumab, while the other, known as MK-6482, is an inhibitor of HIF-2ɑ given as monotherapy.
Cervical Cancer Elimination in Low-Income and Lower-Middle-Income Countries
19.02.2020
A comparative modelling analysis in 78 low-income and lower-middle-income countries (LMICs) suggest that high human papillomavirus (HPV) vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden. The findings are published online on 30 January 2020 in The Lancet.
Cutting off kidney cancer at its roots
18.02.2020
Scientists at the Max Delbrück Centrum for Molecular Medicine (MDC) have discovered stem cells responsible for the most common form of kidney cancer. The team of Walter Birchmeier has found a way to block the growth of these tumors in three models of the disease.
Antibiotic Exposure Worsens Survival and Colitis in Patients With Stage III and IV Melanoma Receiving ICIs
17.02.2020
Patients with stage III and stage IV melanoma receiving immune checkpoint inhibitors (ICIs) had decreased overall survival (OS) and increased melanoma-specific mortality and risk for moderate to severe colitis if they were treated with antibiotics, according to a large retrospective study presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.
Colorectal Cancer in Ulcerative Colitis and Crohn’s Disease
17.02.2020
According to a Scandinavian population-based cohort study, individuals with ulcerative colitis (UC) are at increased risk of developing colorectal cancer (CRC) compared with those without UC, are diagnosed with less advanced CRC, and are at increased risk of dying from CRC, although these excess risks have declined substantially over time. Furthermore, patients with Crohn's disease are at increased risk of diagnosis and death from CRC. Patients with Crohn's disease who have CRC have a higher mortality than patients without Crohn's disease who are also diagnosed with CRC.
Urine-Based RNA Assays Show Promise for Diagnosis, Classification of Prostate Cancer
15.02.2020
Analysis of small non-coding RNA (sncRNA) from a single urine sample could offer a simple and accurate way to diagnose prostate cancer and differentiate between low- and high-grade, high-risk forms of the malignancy, according to a new study.
HPV Vaccine Hesitancy
15.02.2020
Although the human papillomavirus (HPV) vaccine is still included in the Japanese national immunisation programme and is provided free of charge for girls aged 12–16 years, the Japanese Government suspended proactive recommendations for the vaccine in June 2013, after unconfirmed reports of adverse events following immunisation appeared in the media. Vaccine coverage declined rapidly from more than 70% to less than 1%. It is estimated that the HPV vaccine crisis result to date in around 5000 deaths from cervical cancer in Japan.
Vitamin D Intake May Reduce Risk of Immune Checkpoint Inhibitor–Induced Colitis
15.02.2020
Patients who were taking vitamin D supplements when initiating immune checkpoint inhibitor (ICI) therapy had significantly reduced odds of developing ICI–related colitis, according to a retrospective study (Abstract 89) presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.
Study Surveys Molecular Landscape of Endometrial Cancer
14.02.2020
The most comprehensive molecular study of endometrial cancer to date has further defined the contributions of key genes and proteins to the disease, say its authors. Published online February 13 in Cell, the study suggests new treatment approaches that could be tailored for each patient, as well as potential biological targets for future drug design.
Treatment of Helicobacter Pylori Infection May Reduce the Risk of Gastric Cancer
13.02.2020
Findings from a study performed in South Korea among persons with Helicobacter pylori infection who had a family history of gastric cancer in first-degree relatives, show that Helicobacter pylori eradication treatment reduced the risk of gastric cancer. The results from this randomised trial are published on 30 January 2020 in The New England Journal of Medicine.
The Role of Adjuvant Radiotherapy in Improving Outcomes for Locally Advanced Bladder Cancer
12.02.2020
Adjuvant RT significantly improves local control and suggest that this improvement in local control may translate to a benefit in survival for patients with bladder cancer. Patients with locally advanced bladder cancer at the time of radical cystectomy have an estimated 5-year overall survival (OS) of only 10% to 40%.1 Approximately one-third will develop a local-regional recurrence at the initial site of failure after surgery, and distant metastases are common.1-3 Adjuvant chemotherapy is frequently employed for patients with locally advanced bladder cancer who did not receive neoadjuvant chemotherapy to address the risk of distant disease.
Treatment with CAR-NK Cells in Patients with Relapsed or Refractory CD19-positive Lymphoid Tumours
11.02.2020
Among 11 patients with relapsed or refractory CD19-positive lymphoid tumours, a majority had a response to treatment with chimeric antigen receptor (CAR) natural killer (NK) cells without the development of major toxic effects. Allogeneic CAR-NK cells can be delivered in adoptive transfer without the serious cytokine release syndrome and neurologic toxic effects according to study findings published online on 6 February 2020 in The New England Journal of Medicine.
EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab
10.02.2020
On 30 January 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ruxience (rituximab), intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and Pemphigus vulgaris (PV).
Panel dyskusyjny „Sposób postępowania ze zmianami ogniskowymi u pacjentek z grupy wysokiego ryzyka”
10.02.2020
26 marca w ramach konferencji „Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce. Falenty 2020” odbędzie się panel dyskusyjny „Sposób postępowania ze zmianami ogniskowymi u pacjentek z grupy wysokiego ryzyka – dyskusja przypadków”.
„Onkologia” nowy podręcznik wydawnictwa AsteriaMed
05.02.2020
Nakładem wydawnictwa AsteriaMed ukazała się nowa pozycja o tematyce onkologicznej, uwzględniająca najnowszy i aktualny stan wiedzy, zatytułowana „Onkologia. Podręcznik dla studentów medycyny. Pomoc dydaktyczna dla lekarzy specjalizujących się w onkologii”.
Akademia Raka Jelita Grubego 2020
30.01.2020
Ruszyła 2. edycja Akademii Raka Jelita Grubego – cyklu konferencji skierowanych do lekarzy wszystkich specjalizacji zaangażowanych w leczenie chorych na raka jelita grubego.
Konferencja Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce „Falenty 2020”
27.01.2020
W imieniu organizatorów zapraszamy na XIV Międzynarodową Konferencję Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce „Falenty 2020” organizowaną przez Polskie Towarzystwo do Badań nad Rakiem Piersi. Konferencja odbędzie się w Warszawie 26-28 marca 2020 roku.
XXV Konferencja Naukowa Postępy w Ginekologii Onkologicznej
06.01.2020
W imieniu profesora Zbigniewa Kojsa – Konsultanta Krajowego w Dziedzinie Ginekologii Onkologicznej oraz Organizatorów zapraszamy do udziału w Konferencji Naukowej „Postępy w Ginekologii Onkologicznej”. Celem Konferencji jest doskonalenie wiedzy onkologicznej wśród lekarzy ginekologów. Odbędzie się ona 10-11 września 2020 r. w Hotelu Mercure Kasprowy w Zakopanem.
NU-MED Onkologia
Grupa NU-MED to wyspecjalizowane placówki, w których diagnozujemy i leczymy pacjentów z chorobami nowotworowymi. Leczenie odbywa się w ramach kontraktu z NFZ. Zobacz więcej informacji.
Onkodiag – medycyna spersonalizowana w onkologii
Badania oparte na wnikliwej analizie tkanek pochodzących z nowotworu oraz krążących we krwi komórek nowotworowych:
- Trublood – nieinwazyjna biopsja z analizą pod kątem diagnozy, rokowań i teranostyki
- Celldx – głęboka analiza genomiczna nowotworu – badanie skuteczności terapii
- Exacta – pełna analiza nowotworu uwzględniająca genomikę, immunohistochemię, immunocytochemię i chemowrażliwość żywych komórek. Badanie zaprojektuje najbardziej skuteczne leczenie
- Chemoscale – badanie chemowrażliwości leków cytostatycznych
- Cancertrack – monitorowanie efektów leczenia na podstawie cell-free DNA